Dr Peter Finan, Chairman
Dr Peter Finan is Partner at Epidarex Capital and currently serves on the board of Clyde Bioscienes, Caldan Therapeutics, Enterprise Therpeutics and Topas Therapeutics. Prior to joining Epidarex, Dr Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Dr Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas). Dr Finan holds a BSc and PhD in Biochemistry and Molecular Biology from the University of Leeds.
Dr John Ford, Chief Executive Officer
Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. As a successful biotechnology entrepreneur he co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). At Xention he was responsible for the Kv1.5 ion channel atrial fibrillation project which was partnered to Servier (up to 120M EUR). Recently, he was a member of the Executive Team at Dezima (COO) that developed TA-8995 for dyslipidaemia (Phase 2b study published in The Lancet) and sold the company to Amgen ($300M upfront, potential deal size of US$1.55bn + royalties). Previous positions include Team Leader for Receptors and Channel Drug Discovery at BioFocus (now owned by Charles River). Dr Ford holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Prof Martin Gosling, Chief Scientific Officer
Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. Prior to co-founding Enterprise Therapeutics, Prof Gosling was Executive Director in the Respiratory Disease Area of the Novartis Institutes for BioMedical Reseach, UK. Whilst with Novartis he established an internal ion channel platform, was a successful Project Team leader for multiple drug discovery programs and played a lead role in defining the Novartis cystic fibrosis (CF) portfolio. Prof Gosling holds a BSc and PhD in Pharmacology from the Universities of Leeds and Aston respectively. In addition to his position as CSO of Enterprise Therapeutics, he also holds the position of Professor of Molecular Pharmacology at the University of Sussex.
Dr. Liz Roper, Investor Director
Dr Liz Roper is Partner at Epidarex Capital Capital and currently serves on the board of Edinburgh Molecular Imaging, Caldan Therapeutics, Enterprise Therapeutics and Nodthera. She has more than 15 years experience in the Life Science and Healthcare industry. Prior to joining Epidarex, Dr Roper was the Head of Business Development at Chroma Therapeutics, an Oxford-based venture-backed drug discovery and development company focused on inflammatory disorders and oncology. She is a former executive with the Life Science venture capital team at the Investments Division of The Wellcome Trust and also a former member of the Life Science team at Atlas Ventures, London. Dr Roper holds a BSc in Biochemistry (1st class) from the University College Cork, and a PhD from the Imperial Cancer Research Fund.
Dr Rob Woodman, Investor Director
Dr Rob Woodman is Director of Healthcare Investments at Imperial Innovations, and currently serves on the board of Mission Therapeutics, Crescendo Biologics, Inivata, Enterprise Therapeutics and Nascient Therapeutics. Rob joined Innovations in 2012 and was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRT) through to pharmaceutical consultancy with IMS Health. Rob holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.
Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets within Europe and US.
Touchstone Innovations is focused on commercialising the best in UK academic research, drawn from academic centres with end-to-end capability, taking research at the earliest stage and working with it right through to commercialisation.